|
|
Best of ASCO Boston > Meeting Program
Best of ASCO Boston Program Agenda
Jump to day: Thursday | Friday | Saturday Faculty Disclosures
Abstract titles will be posted on this page on April 25, 2012, and confirmed speakers will be posted as they become available.
4:00 - 7:30 PM Maintenance of Certification (MOC) Workshop
An interactive session that will use audience-response technology to review one medical oncology SEP module. At the completion of the session, ABIM diplomats will be able to submit their answers to the ABIM for Maintenance of Certification credit. Registration for this session is open to all Meeting attendees; however, due to limited space, we encourage only those enrolled in MOC to register.
| |
|
7:15 AM — 3:30 PM
|
Exhibits Open (Exhibits open on day 1 only)
|
|
7:15 AM — 8:00 AM
|
Complimentary Continental Breakfast Provided
|
|
8:00 AM
|
Welcome and Chair Remarks
Harold J. Burstein, MD, PhD - Dana-Farber Cancer Institute
|
|
8:00 AM — 8:45 AM
|
Gastrointestinal (Non-colorectal) Cancer
Theodore S. Hong, MD – Massachusetts General Hospital
- Abstract #LBA4000: A randomized, multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab in advanced esophagogastric cancer (REAL3). (T. Waddell)
- Abstract #LBA4003: Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial. (T.Conroy)
- Abstract #4004: Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: Results of ACT II. (R. Glynne-Jones)
- Abstract #4008: A randomized controlled phase II study of the prophylactic effect of urea-based cream on the hand-foot skin reaction associated with sorafenib in advanced hepatocellular carcinoma. (Z. Ren)
Read ASCO Daily News coverage for the following abstracts:
|
|
8:45 AM — 9:45 AM
|
Gastrointestinal (Colorectal) Cancer
Weijing Sun, MD - University of Pennsylvania Cancer Center
- Abstract #LBA3500^: Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev in patients with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM phase III trial. (C. Tournigand)
- Abstract #LBA3501: Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). (J. C. Bendell)
- Abstract #3502: Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC). (E. Van Cutsem)
- Abstract #CRA3503: Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). (D. Arnold)
- Abstract #3505: Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen. (C. J. Allegra)
- Abstract #3508: EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results. (B. Nordlinger)
- Abstract #3513: The prognostic importance of miRNA-21 in stage II colon cancer: A population-based study. (S. Kjaer-Frifeldt)
Read ASCO Daily News coverage for the following abstracts:
|
|
9:45 AM — 10:00 AM
|
Break
|
|
10:00 AM — 10:45 AM
|
Gynecologic Cancer
Don S. Dizon, MD - Brown Medical School
- Abstract #LBA5000: Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study. (I. B. Vergote)
- Abstract #LBA5002^: AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC). (E. Pujade-Lauraine)
- Abstract #5003: Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. (N. Katsumata)
- Abstract #5006: A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505). (R. Kitagawa)
Read ASCO Daily News coverage for the following abstracts:
|
|
10:45 AM — 11:30 AM
|
Head and Neck Cancer
Christine Chung, MD - The Johns Hopkins University
- Abstract #5500: DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). (E. E. W. Cohen)
- Abstract #5501: The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC). (R. I. Haddad)
- Abstract #5502: A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). (J. Giralt)
- Abstract #5508: An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. (P. Schoffski)
|
|
11:30 AM — 12:00 PM
|
Central Nervous System Tumors
L. Burt Nabors, MD - University of Alabama at Birmingham Comprehensive Cancer Center
- Abstract #2: Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD). (M. J. Van Den Bent)
- Abstract #2008b: Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendroglioma: Long-term results of the RTOG 9402 phase III study. (J. G. Cairncross)
Read ASCO Daily News coverage for the following abstracts:
|
|
12:00 PM — 12:45 PM
|
Complimentary Boxed Lunch Provided
|
|
12:45 PM — 1:15 PM
|
Faculty Case Question & Answer Panel
Open-attendance question-and-answer panel with faculty, where attendees can seek the panel’s expert advice on challenging patient cases and issues raised during the Meeting presentations
- Harold J. Burstein, MD, PhD - Dana-Farber Cancer Institute
- Theodore S. Hong, MD - Massachusetts General Hospital
- Weijing Sun, MD -University of Pennsylvania Cancer Center
- Don S. Dizon, MD - Brown Medical School
- Christine Chung, MD - The Johns Hopkins University
- L. Burt Nabors, MD - University of Alabama at Birmingham Comprehensive Cancer Center
|
|
1:15 PM — 2:00 PM
|
Education Session
Supriya G. Mohile, MD - University of Rochester Medical Center
- Adjuvant Therapy for Older Adults
- Treatment of Older Patients with Advanced Cancer: Balancing Efficacy with Toxicity
|
|
2:00 PM — 2:45 PM
|
Melanoma/Skin Cancers
Michael S. Sabel, MD, FACS – University of Michigan
- Abstract #LBA8500^: Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma. (A. Hauschild)
- Abstract #8501: BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets). (J. M. Kirkwood)
- Abstract #8504: Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG. (L. E. Flaherty)
- Abstract #8507: Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL). (F. S. Hodi)
- Abstract #LBA8509: METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM). (C. Robert)
Read ASCO Daily News coverage for the following abstracts:
|
|
2:45 PM — 3:15 PM
|
Sarcoma
William D. Tap, MD – Memorial Sloan-Kettering Cancer Center
- Abstract #LBA10008: Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial. (G. D. Demetri)
- Abstract #10009: PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients. (W. T. A. Van Der Graaf)
Read ASCO Daily News coverage for the following abstracts:
|
|
3:15 PM — 3:30 PM
|
Break
|
|
3:30 PM — 4:30 PM
|
Genitourinary Cancer
William K. Oh, MD – Mt. Sinai School of Medicine, Tisch Cancer Institute
- Abstract #4: Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. (M. Hussain)
- Abstract #4501: Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. (R. J. Motzer)
- Abstract #LBA4512: Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). (C. Parker)
- Abstract #LBA4518: Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (C. J. Ryan)
- Abstract #4519^: Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. (J. S. De Bono)
Read ASCO Daily News coverage for the following abstracts:
|
|
|
|
7:15 AM — 8:00 AM
|
Complimentary Continental Breakfast Provided
|
|
8:00 AM — 8:45 AM
|
Breast Cancer - HER2/ER+
Harold J. Burstein, MD, PhD – Dana-Farber Cancer Institute
- Abstract #LBA1: Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. (K. L. Blackwell)
- Abstract #501: Effect of osteoporosis in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27. (L. E. Shepherd)
- Abstract #502: Adjuvant therapy with zoledronic acid (AZURE-BIG 01/04): The influence of menopausal status and age on treatment effects. (H. Marshall)
- Abstract #LBA671: Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. (K. A. Gelmon)
Read ASCO Daily News coverage for the following abstracts:
|
|
8:45 AM — 9:45 AM
|
Breast Cancer - Triple-Negative/Local Therapy
Steven J. Isakoff, MD, PhD - Massachusetts General Hospital
- Abstract #LBA1000: NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC→paclitaxel (P) plus gemcitabine (G) with DD AC→P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. (S. M. Swain)
- Abstract #CRA1002: CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). (H. S. Rugo)
- Abstract #1003: A phase III, multicenter, randomized trial of maintenance versus observation after achieving clinical response in patients with metastatic breast cancer who received six cycles of gemcitabine plus paclitaxel as first-line chemotherapy (KCSG-BR 0702, NCT00561119). (Y. Im)
- Abstract #1004: RTOG 9804: A prospective randomized trial for “good risk” ductal carcinoma in situ (DCIS), comparing radiation (RT) to observation (OBS) (B. McCormick)
- Abstract #1023: Prognostic and predictive impact of Ki-67 before and after neoadjuvant chemotherapy on PCR and survival: Results of the GeparTrio trial. (G. Von Minckwitz)
- Abstract #CRA9513: New insights into the risk of breast cancer in childhood cancer survivors treated with chest radiation: A report from the Childhood Cancer Survivor Study (CCSS) and the Women's Environmental Cancer and Radiation Epidemiology (WECARE) Study. (C. S. Moskowitz)
Read ASCO Daily News coverage for the following abstracts:
|
|
9:45 AM — 10:15 AM
|
Cancer Prevention/Epidemiology
Kala Visvanathan, MD, MHS - The Johns Hopkins University
- Abstract #1500: A phase III prevention trial of low-dose tamoxifen in HRT users: The HOT trial. (B. Bonanni)
- Abstract #1501: Estrogen plus progestin (E+P) and breast cancer incidence and mortality. (R. T. Chlebowski)
- Abstract #1503: Long-term therapy with thiazolidinediones and the risk of bladder cancer: A cohort study. (R. Mamtani)
- Abstract #1504: Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric cancer patients. (D. M. Walker)
Read ASCO Daily News coverage for the following abstracts:
|
|
10:15 AM — 10:30 AM
|
Break
|
|
10:30 AM — 11:15 AM
|
Leukemia
Attaya Suvannasankha, MD - Indiana University
- Abstract #6500: Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed/refractory B-precursor ALL. (M. Topp)
- Abstract #6501: Inotuzumab ozogamycin (I0), a CD22 monoclonal antibody conjugated to calecheamicin, given weekly, for refractory-relapse acute lymphocytic leukemia (R-R ALL). (E. Jabbour)
- Abstract #6503: PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. (J. E. Cortes)
- Abstract #6504: Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up. (A. Hochhaus)
- Abstract #6507: The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study. (J. C. Byrd)
|
|
11:15 AM — 12:00 PM
|
Lymphoma and Myeloma
Michael E. Williams, MD – University of Virginia Medical Center
- Abstract #3: Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. (M. J. Rummel)
- Abstract #8002: ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. (P. P. Carde)
- Abstract #8006: R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL). (M. Federico)
- Abstract #8007: A subgroup analysis of small lymphocytic and marginal zone lymphomas in the Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden indolent non-Hodgkin lymphoma. (M. E. Williams)
- Abstract #8011: Stringent complete response (sCR) in patients (pts) with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX). (A. J. Jakubowiak)
- Abstract #9500: Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study. (Y. P. Mosse)
Read ASCO Daily News coverage for the following abstracts:
|
|
12:00 PM — 12:45 PM
|
Complimentary Boxed Lunch Provided
|
|
12:45 PM — 1:15 PM
|
Faculty Case Question & Answer Panel
Open-attendance question-and-answer panel with faculty, where attendees can seek the panel’s expert advice on challenging patient cases and issues raised during the Meeting presentations
- Harold J. Burstein, MD - Dana-Farber Cancer Institute
- Steven J. Isakoff, MD - Massachusetts General Hospital
- Kala Visvanathan, MD - The Johns Hopkins University
- Attaya Suvannasankha, MD - Indiana University
- Michael E. Williams, MD - University of Virginia Medical Center
|
|
1:15 PM — 2:00 PM
|
Education Session
Roy Herbst, MD - Yale Comprehensive Cancer Center
- Developing a Targeted Therapy: Issues in the Age of Personalized Medicine
- Early Drug Development: Casting a Wide Net Versus Preselecting a Narrow Audience
|
|
2:00 PM — 3:00 PM
|
Patient and Survivor Care
Teresa Gilewski, MD - Memorial Sloan-Kettering Cancer Center
- Abstract #9000: Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms and fatigue in women with breast cancer starting adjuvant letrozole: The VITAL trial. (Q. J. Khan)
- Abstract #9001: Phase III evaluation of American ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N07C2. (D. L. Barton)
- Abstract #9003: Cluster-randomized trial of early palliative care for patients with metastatic cancer. (C. Zimmermann)
- Abstract #9005: ZOOM: A prospective, randomized trial of zoledronic acid (ZOL; q 4 wk vs q 12 wk) for long-term treatment in patients with bone-metastatic breast cancer (BC) after 1 yr of standard ZOL treatment. (D. Amadori)
- Abstract #9512: Evaluation of the effect of care at NCI comprehensive cancer centers (NCICCCs) on disparities in outcome within adolescents and young adults (AYAs) with cancer. (J. A. Wolfson)
- Abstract #CRA9013: CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN). (E. M. Lavoie Smith)
Read ASCO Daily News coverage for the following abstracts:
|
|
3:00 PM — 3:45 PM
|
Lung Cancer - Improvements in Current Therapy Standards
Ramaswamy Govindan, MD - Washington University School of Medicine
- Abstract #7000: Is consolidation chemotherapy after concurrent chemoradiotherapy beneficial for locally advanced non-small cell lung cancer? A pooled analysis of the literature. (S. Yamamoto)
- Abstract #7004: Phase III trial of concurrent thoracic radiotherapy (TRT) with either the first cycle or the third cycle of cisplatin and etoposide chemotherapy to determine the optimal timing of TRT for limited-disease small cell lung cancer. (K. Park)
- Abstract #7008: Accuracy of FDG-PET to diagnose lung cancer in the ACOSOG Z4031 trial. (E. L. Grogan)
- Abstract #7506: A randomized phase III trial of single agent pemetrexed (P) versus carboplatin and pemetrexed (CP) in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2. (R. Lilenbaum)
- Abstract #6004: Effect of early palliative care on health care costs in patients with metastatic NSCLC. (J. A. Greer)
Read ASCO Daily News coverage for the following abstracts:
|
|
3:45 PM — 4:30 PM
|
Lung Cancer - Molecular Findings and Targeted Therapies
Nathan Pennell, MD, PhD - The Cleveland Clinic
- Abstract #7006: Comprehensive genomic characterization of squamous cell carcinoma of the lung. (R. Govindan)
- Abstract #LBA7500: LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. (J. C. H. Yang)
- Abstract #LBA7501: TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild type (wt) EGFR. (M. C. Garassino)
- Abstract #7508: Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. (A. T. Shaw)
- Abstract #7509: Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC). (J. R. Brahmer)
Read ASCO Daily News coverage for the following abstracts:
|
4:30 PM
|
Meeting Adjourns
|
|
Highlights - Meeting Program Agenda now available
|